Snitker S, Egebjerg C, Frederiksen M, Sparre T, et al. Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial. Diabetes Obes Metab 2022;24:2273-2276.
PMID: 35791625